Results for "CagriSema"
12 stories found
Barclays slashes sales forecasts for Novo's CagriSema by more than 80% - Reuters
Barclays slashes sales forecasts for Novo's CagriSema by more than 80% Reuters
Topchef holder fast i potentiale for vægttabshåb trods nye data
Doustdar tror, at Cagrisema bliver det bedste på markedet. Nye data viser højere vægttab med et andet middel.
Novo Nordisk's CEO Says Still 'Incredibly Optimistic' About CagriSema - TradingView
Novo Nordisk's CEO Says Still 'Incredibly Optimistic' About CagriSema TradingView
Healthy Returns: What’s next for Novo Nordisk’s next-generation obesity drug CagriSema after trial miss
The Danish drugmaker released late-stage data showing that the upcoming injection CagriSema failed to match the weight loss of Eli Lilly’s Zepbound.
Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is labelled ‘obsolete’
Novo Nordisk’s shares fall sharply after testing of CagriSema falls short of investors’ expectations
Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly's in trial
Novo Nordisk stock fell as much as 10% Monday after it said its next-generation weight loss drug didn't meet its primary target.
Novo Nordisk-aktie lukker i laveste kurs siden 2021
Cagrisema viser et lavere vægttab end Eli Lillys aktive stof tirzepatid i et nyt studie. Novo-aktien falder til laveste niveau i fem år.
Novo's stumbles burnish Lilly's widening lead in weight-loss drugs - Reuters
Novo's stumbles burnish Lilly's widening lead in weight-loss drugs Reuters
Novo Nordisk's Next-Gen Weight-Loss Drug CagriSema Deemed 'Obsolete' After Disappointing Trial Results
Shares of Novo Nordisk, owner of Wegovy and Ozempic, fell sharply after its highly anticipated next-generation weight-loss drug, CagriSema, failed to meet investor expectations in testing, leading it to be branded 'obsolete'.
Novo Nordisk shares drop 10% after poor weight loss trial result
Once-a-week injection achieved weight loss of 23%, which is lower than some existing treatments
Novo Nordisk Stock Falls After Weight Loss Drug Data
Novo Nordisk's stock dropped significantly after new data showed its experimental weight-loss drug Cagrisema was less effective than Eli Lilly's tirzepatide.